Inventage Lab, a drug delivery platform company, saw its stock surge early in the day after receiving news of an additional patent decision in the United States for its long-acting injectable drug for treating drug addiction.
As of 9 a.m. on the 21st, Inventage Lab's shares were trading at 31,450 won, up 23.58% from the previous trading day, according to the Korea Exchange.
The surge is attributed to the announcement that the company’s long-acting injectable drug, IVL3004, has received a patent registration decision from the U.S. Patent and Trademark Office (USPTO).
Inventage Lab stated that the patent pertains to a formulation and manufacturing method for a sustained-release injectable composition containing naltrexone.
IVL3004 is a monthly injectable drug primarily composed of naltrexone, developed for the treatment of alcohol and drug dependence.
The patent includes a composition and manufacturing method for microparticles with specific pharmacokinetic properties and uniform particle size distribution.
It protects the formulation characteristics and manufacturing technology that control the rapid initial release of the drug while ensuring continuous release over a month.
The company plans to utilize this patent in its U.S. clinical development and future global technology transfer and co-development processes. By securing patent protection for both the formulation and the manufacturing methods necessary for commercial production, Inventage Lab aims to establish the scope of rights for IVL3004 during future partnering efforts.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.